Skip to content

Preliminary Study of Uterine Healing After Caesarean Section: CLInico-ECHOgraphic and Anatomopathologic COrrelation

Preliminary Study of Uterine Healing After Caesarean Section: CLInico-ECHOgraphic and Anatomopathologic COrrelation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05785559
Acronym
COCLIECHO
Enrollment
90
Registered
2023-03-27
Start date
2023-04-01
Completion date
2024-07-01
Last updated
2023-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assessment of Uterine Healing

Keywords

uterine scarring, isthmocele, caesarean section

Brief summary

Caesarean section is one of the most common surgical procedures. The multiplication of uterine scars leads to an increase in complications and in particular those related to poor healing such as isthmocele or uterine rupture. The processes of uterine healing at the histological scale are little known. The main objective of the research is to analyze the process of uterine healing by means of uterine biopsies performed on the areas of cesarean section scars.

Detailed description

Our hypothesis is that there is a histological healing defect visible on an anatomopathologic examination of the scar. This poor uterine healing on histological scale is probably associated with uterine healing defects visible on pelvic ultrasound (scar dehiscence) and clinical criteria (number of caesareans, symptoms). The objective of the research is to analyze uterine scarring by means of uterine biopsies performed on the areas of cesarean section scars. The uterine scarred areas will be analyzed histologically according to specific criteria and compared to healthy uterine areas. Histological characteristics will be compared with clinical and ultrasound data.

Interventions

PROCEDUREuterine biopsies

uterine biopsies performed on the areas of cesarean section scars

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Uterine biopsy and cesarean scar dehiscence

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Common to all groups: * Adult patient, * Signed consent for participation in the study * Patient affiliated to a social security scheme (excluding AME) Group 1: * Support for a scheduled or emergency caesarean (excluding patients having an emergency caesarean (red code: caesarean within 15 minutes)) * Scarred uterus: having already benefited from a caesarean section Group 2: \- Surgical management of caesarean section scar dehiscence after a caesarean section Group 3 (control): * Support for a scheduled or emergency caesarean (excluding patients having an emergency caesarean (red code: caesarean within 15 minutes) * Healthy uterus: no history of caesarean section (history of vaginal delivery or first pregnancy)

Exclusion criteria

* Disorder of hemostasis at risk of bleeding * Anatomopathological sampling not feasible * Patient with a history of upper genital infections * Patient under legal protection (guardianship, curatorship) * Patient who does not speak or understand French * Patient unable to answer questions or with difficulty in expressing herself

Design outcomes

Primary

MeasureTime frameDescription
Analyze the process of uterine healing8 weeksThe main objective of the research is to analyze the process of uterine healing by means of uterine biopsies performed on the areas of cesarean section scars

Secondary

MeasureTime frameDescription
Histological aspects of the scar8 weeksThe secondary evaluation criteria will be the correlation of the histological aspects of the scar with the clinical and ultrasound data. The objective is to look for risk factors for poor uterine healing.

Countries

France

Contacts

Primary ContactPerrine CAPMAS
perrine.capmas@aphp.fr0145217714

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026